Shire selects IDBS for virtualized drug research collaboration platform

E-WorkBook Provides IP and Data Management Platform for Collaborative R&D

Guildford, UK, and Burlington, Mass., April 14, 2010 - IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that Shire plc, the global specialty biopharmaceutical company, has selected IDBS to support its virtual model for pharmaceutical research.

Shire will implement IDBS' E-WorkBook Suite in a collaborative environment with its CROs to streamline and facilitate its new drug research in 2010 and the future. By leveraging hosted services in combination with E-WorkBook, Shire will have a minimum IT footprint both in-house and at each CRO, eliminating the need for on-site data storage, providing secure access to remote data, facilitating collaboration and reducing bottlenecks in knowledge transfer between organizations. When combined with the secure, compliant environment of E-WorkBook to more effectively manage IP, this makes a state-of-the-art platform for virtual drug research.

E-WorkBook is a scalable, searchable and secure environment for the capture, management and sharing of R&D data. E-WorkBook's capabilities are further enhanced by hosting in a cloud-based environment, providing extensible computing power and flexible data storage. The sophisticated security model provided by E-WorkBook addresses concerns around cloud computing and data security, and delivers secure import of data from multiple CROs and partners with no risk of security breaches.

For this implementation, IDBS' solution will be provided in collaboration with Quantix Ltd, using its hosted infrastructure to provide Shire with complete flexibility in the choice, size and diversity of their drug research collaborations.

"Shire is pleased to contribute to the application of the IDBS platform to the virtual drug research model. This new technology will support our remote vendor partnership relationships, and enhance the transfer, review and searching of data across our exploratory projects," said Dr Stephen Damment, Senior Vice President of Biosciences at Shire. "The IDBS team understands the requirements of the life sciences research space, and has experience working with multiple partners and technologies to help implement scientific data management solutions."

"Shire is at the forefront of virtualized exploratory drug research, implementing new ways of working with their CRO partners, and we are delighted that they have chosen to work with our innovative technology," said Neil Kipling, founder and CEO of IDBS. "IDBS continues to provide solutions that meet our customers' specific needs, and is pleased to have delivered a hosted, virtual environment to support their collaborations."

About IDBS

IDBS is a unique, global supplier of innovative data management and analytics solutions, which increase efficiency, reduce costs and improve business and scientific productivity of R&D organizations worldwide. Organizations such as Pfizer, GSK, Celera, MedImmune, Dana-Farber, and Roche employ IDBS solutions as an integral part of their strategy to address the increasing pressures placed upon them by the need for the secure, compliant capture, integration and analysis of complex research data. IDBS is clearly differentiated from other software providers by its unique combination of deep domain knowledge and its ability to rapidly provide integrated business process and robust data analytics solutions along the entire R&D value chain. IDBS solutions secure organizations' valuable R&D data assets and enable rapid decision-making through effective integration and analysis. They also support the protection of Intellectual Property (IP) and the requirements for data quality demanded under Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards.

IDBS is a private company, founded in 1989 and headquartered in Guildford, UK. IDBS has worldwide consulting and support presence, with U.S. offices in California, New Jersey and Massachusetts, the EU, Australia and China.